The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis

Clin Endocrinol (Oxf). 1999 Jan;50(1):37-44. doi: 10.1046/j.1365-2265.1999.00592.x.

Abstract

Objective: Recent reports suggest that complex interactions exist between the neuroendocrine and immune systems. It has been shown for example that cytokines are able to stimulate the hypothalamo-pituitary-adrenal axis. In addition, some studies present evidence that endothelin is able to modulate the activity of several hypothalamic-pituitary axes, e.g. by inducing the ACTH production.

Design: We investigated the effects of interleukin-2 on endothelin levels and the hypothalamo-pituitary-adrenal axis. We determined the interleukin-6, big-endothelin, endothelin-1, ACTH, cortisol and AVP responses to intravenously and subcutaneously administered interleukin-2 in 8 cancer patients in a randomized placebo controlled trial.

Patients: 8 Patients (2 female and 6 male), age 44 +/- 4.8 years, were enrolled. All patients had a World Health Organization performance status of 1 or less and a Karnofsky Index of at least 80%.

Measurements: Blood-samples were taken before and 15, 30, 45, 60, 120, 180, 240, 300 and 360 min after interleukin-2 injection. Cytokine serum levels and the plasma levels of big-endothelin, endothelin, ACTH and AVP were analysed using radioimmuno-assays. Cortisol was assayed by an enzyme-linked immunosorbent assay.

Results: Interleukin-2 treatment significantly increased plasma big-endothelin levels (P < 0.01 vs basal) and endothelin-1 levels (P < 0.05 vs basal) within two hours and this was followed by an increase in ACTH (P < 0.01 vs basal) and cortisol (P < 0.05 vs basal) within three hours. Interleukin-6 levels increased two hours after interleukin-2 administration (P < 0.01 vs basal). Interleukin-2 had no detectable effect on AVP, blood pressure or heart rate.

Conclusions: Our data demonstrate that cytokines are able to activate the human hypothalamo-pituitary-adrenal axis in vivo. On the basis of the observed time kinetics and in connection with previous findings from in vitro and animal models, we conclude that endothelin may be a link between cytokines and corticotrophin-releasing hormone, most probably functioning as a cytokine-induced neuromodulator controlling pituitary functions.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adrenocorticotropic Hormone / blood
  • Adult
  • Arginine Vasopressin / blood
  • Endothelin-1
  • Endothelins / blood*
  • Female
  • Humans
  • Hydrocortisone / blood
  • Hypothalamo-Hypophyseal System / drug effects*
  • Hypothalamo-Hypophyseal System / physiology
  • Interleukin-2 / therapeutic use*
  • Interleukin-6 / blood
  • Kidney Neoplasms / blood
  • Kidney Neoplasms / therapy
  • Male
  • Melanoma / blood
  • Melanoma / therapy
  • Middle Aged
  • Neoplasms / blood
  • Neoplasms / therapy*
  • Pituitary-Adrenal System / drug effects*
  • Pituitary-Adrenal System / physiology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Protein Precursors / blood
  • Stimulation, Chemical

Substances

  • Endothelin-1
  • Endothelins
  • Interleukin-2
  • Interleukin-6
  • Protein Precursors
  • Arginine Vasopressin
  • Adrenocorticotropic Hormone
  • Hydrocortisone